# FDA 483 - Suresh Anne, M.D. - February 13, 2026

Source: https://www.keypedia.com/records/483/suresh-anne-md/42c11be6-f2e0-4338-920b-39468eb38f62

> FDA 483 for Suresh Anne, M.D. on February 13, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Suresh Anne, M.D.
- Inspection Date: 2026-02-13
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations III
- Summary: An FDA inspection of Suresh Anne, M.D., a clinical investigator in Flint, MI, revealed significant deviations from investigational plans and protocols. The firm failed to enroll eligible subjects and did not follow required safety monitoring procedures for investigational products. Additionally, the investigator did not promptly report non-serious adverse events to the sponsor as required by the study protocol.

## Related Documents

- [483 - 2023-05-19](https://www.keypedia.com/records/483/suresh-anne-md/835ef1c5-7a38-4bca-a031-10893a2b967f)

## Related Officers

- [investigator](https://www.keypedia.com/people/dina-a-tallman/e9bf2b98-6697-4d7c-9052-84339536acfd)
- [Victoria R. Flournoy](https://www.keypedia.com/people/victoria-r-flournoy/f8bdf401-7e11-4706-9d36-d8eab4fe46ff)

Company: https://www.keypedia.com/companies/suresh-anne-md/224b7a49-5956-463a-85ec-097c5b1d8fac

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iii/45bc2d0d-d731-4955-aeb5-59aa0b76e4f0